Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
|Videos|December 9, 2021
Virtual genetics board to discuss high-risk localized prostate cancer, BRCA1-related management
Author(s)Urology Times staff
“We will also cover options for germline testing—different ways that tests can be ordered, panel options that are available commercially,” says Veda N. Giri, MD.
Advertisement
In this video, Veda N. Giri, MD, offers a preview of the ENGAGEMENT Study Virtual Genetics Board’s upcoming case discussion, which you can sign up for by going to
Advertisement
Related to this article
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how work force gaps may affect comprehensive infertility evaluations.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Advertisement
Advertisement
Trending on Urology Times
1
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
2
Infertility care: Examining geographic gaps in access
3
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
4
Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamide
5